Biomarkers, Biosensors and Biomedicine

Author(s): Weslley Felix de Oliveira, Priscila Marcelino dos Santos Silva, Luana Cassandra Breitenbach Barroso Coelho*, Maria Tereza dos Santos Correia*

Journal Name: Current Medicinal Chemistry

Volume 27 , Issue 21 , 2020


  Journal Home
Translate in Chinese
Become EABM
Become Reviewer
Call for Editor

Abstract:

The discovery of new biomarkers associated with cancer, neurological and cardiovascular diseases is necessary, since these are common, recurrent diseases considered as leading causes of death in the human population. Molecular signatures of these disorders that can be identified at the outset of their pathogenesis leading to prompt and targeted treatment may increase patient survival. Cancer is a heterogeneous disease that can be expressed differently among individuals; in addition, treatments may have a differentiated approach according to the type of malignant neoplasm. Thus, these neoplastic cells can synthesize and release specific molecules depending on the site where carcinogenesis begins. Moreover, life expectancy is increasing especially in developed countries, however, cases of neurodegenerative diseases have grown in the older members of the population. Commonly, some neurological disorders, which can occur physiologically by the process of senescence, are confused with Alzheimer's Disease (AD). In addition, cardiovascular diseases are the main cause of death in the world; studies capable of identifying, through molecular probes, the beginning of development of an atherosclerotic process can lead to early treatment to avoid an acute myocardial infarction. Accuracy in the detection of these biomarkers can be obtained through biosensors whose design has been increasingly studied to elaborate inexpensive sensory platforms capable of precise detection, even at low concentrations, of the molecule to be measured. The aim of this review is to address biomarkers to be used in diagnoses instead of invasive exams; biosensors for the specific and sensitive detection of these biological markers are also investigated.

Keywords: Biomarkers, diagnosis, cancer, neurological disease, cardiovascular disease, biosensor.

[1]
Geyer, P.E.; Holdt, L.M.; Teupser, D.; Mann, M. Revisiting biomarker discovery by plasma proteomics. Mol. Syst. Biol., 2017, 13(9), 942.
[http://dx.doi.org/10.15252/msb.20156297] [PMID: 28951502]
[2]
Liu, R.; Wang, X.; Aihara, K.; Chen, L. Early diagnosis of complex diseases by molecular biomarkers, network biomarkers, and dynamical network biomarkers. Med. Res. Rev., 2014, 34(3), 455-478.
[http://dx.doi.org/10.1002/med.21293] [PMID: 23775602]
[3]
Kang, H.J.; Jeon, S.Y.; Park, J.S.; Yun, J.Y.; Kil, H.N.; Hong, W.K.; Lee, M.H.; Kim, J.W.; Jeon, J.P.; Han, B.G. Identification of clinical biomarkers for pre-analytical quality control of blood samples. Biopreserv. Biobank., 2013, 11(2), 94-100.
[http://dx.doi.org/10.1089/bio.2012.0051] [PMID: 23634248]
[4]
Kovac, J.R.; Pastuszak, A.W.; Lamb, D.J. The use of genomics, proteomics, and metabolomics in identifying biomarkers of male infertility. Fertil. Steril., 2013, 99(4), 998-1007.
[http://dx.doi.org/10.1016/j.fertnstert.2013.01.111] [PMID: 23415969]
[5]
Khoury, M.J.; Gwinn, M.L.; Glasgow, R.E.; Kramer, B.S. A population approach to precision medicine. Am. J. Prev. Med., 2012, 42(6), 639-645.
[http://dx.doi.org/10.1016/j.amepre.2012.02.012] [PMID: 22608383]
[6]
Hood, L.; Flores, M. A personal view on systems medicine and the emergence of proactive P4 medicine: predictive, preventive, personalized and participatory. N. Biotechnol., 2012, 29(6), 613-624.
[http://dx.doi.org/10.1016/j.nbt.2012.03.004] [PMID: 22450380]
[7]
Flores, M.; Glusman, G.; Brogaard, K.; Price, N.D.; Hood, L. P4 medicine: how systems medicine will transform the healthcare sector and society. Per. Med., 2013, 10(6), 565-576.
[http://dx.doi.org/10.2217/pme.13.57] [PMID: 25342952]
[8]
Barger, J.F.; Rahman, M.A.; Jackson, D.; Acunzo, M.; Nana-Sinkam, S.P. Extracellular miRNAs as biomarkers in cancer. Food Chem. Toxicol, 2016, 98(Pt A), 66-72.
[http://dx.doi.org/10.1016/j.fct.2016.06.010]
[9]
Falanga, A.; Marchetti, M. Hemostatic biomarkers in cancer progression. Thromb. Res., 2018, 164(Suppl. 1), S54-S61.
[http://dx.doi.org/10.1016/j.thromres.2018.01.017] [PMID: 29703485]
[10]
Sumbal, S.; Javed, A.; Afroze, B.; Zulfiqar, H.F.; Javed, F.; Noreen, S.; Ijaz, B. Circulating tumor DNA in blood: Future genomic biomarkers for cancer detection. Exp. Hematol., 2018, 65, 17-28.
[http://dx.doi.org/10.1016/j.exphem.2018.06.003] [PMID: 29940219]
[11]
Kai, K.; Dittmar, R.L.; Sen, S. Secretory microRNAs as biomarkers of cancer. Semin. Cell Dev. Biol., 2018, 78, 22-36.
[http://dx.doi.org/10.1016/j.semcdb.2017.12.011] [PMID: 29258963]
[12]
Farah, R.; Haraty, H.; Salame, Z.; Fares, Y.; Ojcius, D.M.; Said Sadier, N. Salivary biomarkers for the diagnosis and monitoring of neurological diseases. Biomed. J., 2018, 41(2), 63-87.
[http://dx.doi.org/10.1016/j.bj.2018.03.004] [PMID: 29866603]
[13]
Henriques, A.D.; Benedet, A.L.; Camargos, E.F.; Rosa-Neto, P.; Nóbrega, O.T. Fluid and imaging biomarkers for Alzheimer’s disease: Where we stand and where to head to. Exp. Gerontol., 2018, 107, 169-177.
[http://dx.doi.org/10.1016/j.exger.2018.01.002] [PMID: 29307736]
[14]
Khodadadian, A.; Hemmati-Dinarvand, M.; Kalantary-Charvadeh, A.; Ghobadi, A.; Mazaheri, M. Candidate biomarkers for Parkinson’s disease. Biomed. Pharmacother., 2018, 104, 699-704.
[http://dx.doi.org/10.1016/j.biopha.2018.05.026] [PMID: 29803930]
[15]
van Holten, T.C.; Waanders, L.F.; de Groot, P.G.; Vissers, J.; Hoefer, I.E.; Pasterkamp, G.; Prins, M.W.; Roest, M. Circulating biomarkers for predicting cardiovascular disease risk; a systematic review and comprehensive overview of meta-analyses. PLoS One, 2013, 8(4), e62080
[http://dx.doi.org/10.1371/journal.pone.0062080] [PMID: 23630624]
[16]
Huang, Y.; Gulshan, K.; Nguyen, T.; Wu, Y. Biomarkers of cardiovascular disease. Dis. Markers, 2017, 2017, 8208609
[http://dx.doi.org/10.1155/2017/8208609] [PMID: 29238120]
[17]
Zhang, L.; Wan, S.; Jiang, Y.; Wang, Y.; Fu, T.; Liu, Q.; Cao, Z.; Qiu, L.; Tan, W. Molecular elucidation of disease biomarkers at the interface of chemistry and biology. J. Am. Chem. Soc., 2017, 139(7), 2532-2540.
[http://dx.doi.org/10.1021/jacs.6b10646] [PMID: 28121431]
[18]
Jayanthi, V.S.P.K.S.A.; Das, A.B.; Saxena, U. Recent advances in biosensor development for the detection of cancer biomarkers. Biosens. Bioelectron., 2017, 91, 15-23.
[http://dx.doi.org/10.1016/j.bios.2016.12.014] [PMID: 27984706]
[19]
Shui, B.; Tao, D.; Florea, A.; Cheng, J.; Zhao, Q.; Gu, Y.; Li, W.; Jaffrezic-Renault, N.; Mei, Y.; Guo, Z. Biosensors for Alzheimer’s disease biomarker detection: A review. Biochimie, 2018, 147, 13-24.
[http://dx.doi.org/10.1016/j.biochi.2017.12.015] [PMID: 29307704]
[20]
Sund, M.; Kalluri, R. Tumor stroma derived biomarkers in cancer. Cancer Metastasis Rev., 2009, 28(1-2), 177-183.
[http://dx.doi.org/10.1007/s10555-008-9175-2] [PMID: 19259624]
[21]
Wu, L.; Qu, X. Cancer biomarker detection: recent achievements and challenges. Chem. Soc. Rev., 2015, 44(10), 2963-2997.
[http://dx.doi.org/10.1039/C4CS00370E] [PMID: 25739971]
[22]
Chakraborty, S.; Rahman, T. The difficulties in cancer treatment. Ecancermedicalscience, 2012, 6, ed16
[PMID: 24883085]
[23]
Goossens, N.; Nakagawa, S.; Sun, X.; Hoshida, Y. Cancer biomarker discovery and validation. Transl. Cancer Res., 2015, 4(3), 256-269.
[PMID: 26213686]
[24]
Karbasforooshan, H.; Roohbakhsh, A.; Karimi, G. SIRT1 and microRNAs: The role in breast, lung and prostate cancers. Exp. Cell Res., 2018, 367(1), 1-6.
[http://dx.doi.org/10.1016/j.yexcr.2018.03.023] [PMID: 29574020]
[25]
Rohanizadegan, M. Analysis of circulating tumor DNA in breast cancer as a diagnostic and prognostic biomarker. Cancer Genet., 2018, 228-229, 159-168.
[http://dx.doi.org/10.1016/j.cancergen.2018.02.002] [PMID: 29572011]
[26]
Takahashi, H.; Kagara, N.; Tanei, T.; Naoi, Y.; Shimoda, M.; Shimomura, A.; Shimazu, K.; Kim, S.J.; Noguchi, S. Correlation of methylated circulating tumor DNA with response to neoadjuvant chemotherapy in breast cancer patients. Clin. Breast Cancer, 2017, 17(1), 61-69.e3.
[http://dx.doi.org/10.1016/j.clbc.2016.06.006] [PMID: 27395416]
[27]
Ghosh, I.; Bhattacharjee, D.; Das, A.K.; Chakrabarti, G.; Dasgupta, A.; Dey, S.K. Diagnostic role of tumour markers CEA, CA15-3, CA19-9 and CA125 in lung cancer. Indian J. Clin. Biochem., 2013, 28(1), 24-29.
[http://dx.doi.org/10.1007/s12291-012-0257-0] [PMID: 24381417]
[28]
Zhang, S-Y.; Lin, M.; Zhang, H-B. Diagnostic value of carcinoembryonic antigen and carcinoma antigen 19-9 for colorectal carcinoma. Int. J. Clin. Exp. Pathol., 2015, 8(8), 9404-9409.
[PMID: 26464695]
[29]
Attallah, A.M.; El-Far, M.; Ibrahim, A.R.; El-Desouky, M.A.; Omran, M.M.; Elbendary, M.S.; Attallah, K.A.; Qura, E.R.; Abdallah, S.O. Clinical value of a diagnostic score for colon cancer based on serum CEA, CA19-9, cytokeratin-1 and mucin-1. Br. J. Biomed. Sci., 2018, 75(3), 122-127.
[http://dx.doi.org/10.1080/09674845.2018.1456309] [PMID: 29734875]
[30]
Duffy, M.J.; Evoy, D.; McDermott, E.W. CA 15-3: uses and limitation as a biomarker for breast cancer. Clin. Chim. Acta, 2010, 411(23-24), 1869-1874.
[http://dx.doi.org/10.1016/j.cca.2010.08.039] [PMID: 20816948]
[31]
Grunnet, M.; Sorensen, J.B. Carcinoembryonic antigen (CEA) as tumor marker in lung cancer. Lung Cancer, 2012, 76(2), 138-143.
[http://dx.doi.org/10.1016/j.lungcan.2011.11.012] [PMID: 22153832]
[32]
Luong, J.H.T.; Vashist, S.K. Immunosensing procedures for carcinoembryonic antigen using graphene and nanocomposites. Biosens. Bioelectron., 2017, 89(Pt 1), 293-304.
[http://dx.doi.org/10.1016/j.bios.2015.11.053] [PMID: 26620098]
[33]
Porto-Mascarenhas, E.C.; Assad, D.X.; Chardin, H.; Gozal, D.; De Luca Canto, G.; Acevedo, A.C.; Guerra, E.N.S. Salivary biomarkers in the diagnosis of breast cancer: A review. Crit. Rev. Oncol. Hematol., 2017, 110, 62-73.
[http://dx.doi.org/10.1016/j.critrevonc.2016.12.009] [PMID: 28109406]
[34]
Laidi, F.; Bouziane, A.; Errachid, A.; Zaoui, F. Usefulness of salivary and serum auto-antibodies against tumor biomarkers HER2 and MUC1 in breast cancer screening. Asian Pac. J. Cancer Prev., 2016, 17(1), 335-339.
[http://dx.doi.org/10.7314/APJCP.2016.17.1.335] [PMID: 26838233]
[35]
Zhong, L.; Cheng, F.; Lu, X.; Duan, Y.; Wang, X. Untargeted saliva metabonomics study of breast cancer based on ultra performance liquid chromatography coupled to mass spectrometry with HILIC and RPLC separations. Talanta, 2016, 158, 351-360.
[http://dx.doi.org/10.1016/j.talanta.2016.04.049] [PMID: 27343615]
[36]
Gonzalez-Cao, M.; Iduma, P.; Karachaliou, N.; Santarpia, M.; Blanco, J.; Rosell, R. Human endogenous retroviruses and cancer. Cancer Biol. Med., 2016, 13(4), 483-488.
[http://dx.doi.org/10.20892/j.issn.2095-3941.2016.0080] [PMID: 28154780]
[37]
Zhou, F.; Li, M.; Wei, Y.; Lin, K.; Lu, Y.; Shen, J.; Johanning, G.L.; Wang-Johanning, F. Activation of HERV-K Env protein is essential for tumorigenesis and metastasis of breast cancer cells. Oncotarget, 2016, 7(51), 84093-84117.
[http://dx.doi.org/10.18632/oncotarget.11455] [PMID: 27557521]
[38]
Johanning, G.L.; Malouf, G.G.; Zheng, X.; Esteva, F.J.; Weinstein, J.N.; Wang-Johanning, F.; Su, X. Expression of human endogenous retrovirus-K is strongly associated with the basal-like breast cancer phenotype. Sci. Rep., 2017, 7, 41960.
[http://dx.doi.org/10.1038/srep41960] [PMID: 28165048]
[39]
Sumanasuriya, S.; Omlin, A.; Armstrong, A.; Attard, G.; Chi, K.N.; Bevan, C.L.; Shibakawa, A.; IJzerman, M.J.; De Laere, B.; Lolkema, M.; Lorente, D.; Luo, J.; Mehra, N.; Olmos, D.; Scher, H.; Soule, H.; Stoecklein, N.H.; Terstappen, L.W.M.M.; Waugh, D.; de Bono, J.S. Consensus statement on circulating biomarkers for advanced prostate cancer. Eur Urol Oncol, 2018, 1(2), 151-159.
[http://dx.doi.org/10.1016/j.euo.2018.02.009] [PMID: 31100240]
[40]
Kaynar, M.; Yildirim, M.E.; Gul, M.; Kilic, O.; Ceylan, K.; Goktas, S. Benign prostatic hyperplasia and prostate cancer differentiation via platelet to lymphocyte ratio. Cancer Biomark., 2015, 15(3), 317-323.
[http://dx.doi.org/10.3233/CBM-150458] [PMID: 25586096]
[41]
Jiménez-Pacheco, A.; Salinero-Bachiller, M.; Iribar, M.C.; López-Luque, A.; Miján-Ortiz, J.L.; Peinado, J.M. Furan and p-xylene as candidate biomarkers for prostate cancer. Urol. Oncol., 2018, 36(5), 243.e21-243.e27.
[http://dx.doi.org/10.1016/j.urolonc.2017.12.026] [PMID: 29395956]
[42]
Skotland, T.; Ekroos, K.; Kauhanen, D.; Simolin, H.; Seierstad, T.; Berge, V.; Sandvig, K.; Llorente, A. Molecular lipid species in urinary exosomes as potential prostate cancer biomarkers. Eur. J. Cancer, 2017, 70, 122-132.
[http://dx.doi.org/10.1016/j.ejca.2016.10.011] [PMID: 27914242]
[43]
Matin, F.; Jeet, V.; Moya, L.; Selth, L.A.; Chambers, S.; Clements, J.A.; Batra, J.; Batra, J. Australian prostate cancer bioresource. A plasma biomarker panel of four microRNAs for the diagnosis of prostate cancer. Sci. Rep., 2018, 8(1), 6653.
[http://dx.doi.org/10.1038/s41598-018-24424-w] [PMID: 29703916]
[44]
Liu, R.S.C.; Olkhov-Mitsel, E.; Jeyapala, R.; Zhao, F.; Commisso, K.; Klotz, L.; Loblaw, A.; Liu, S.K.; Vesprini, D.; Fleshner, N.E.; Bapat, B. Assessment of serum microRNA biomarkers to predict reclassification of prostate cancer in patients on active surveillance. J. Urol., 2018, 199(6), 1475-1481.
[http://dx.doi.org/10.1016/j.juro.2017.12.006] [PMID: 29246734]
[45]
Fawzy, A.; Sweify, K.M.; El-Fayoumy, H.M.; Nofal, N. Quantitative analysis of plasma cell-free DNA and its DNA integrity in patients with metastatic prostate cancer using ALU sequence. J. Egypt. Natl. Canc. Inst., 2016, 28(4), 235-242.
[http://dx.doi.org/10.1016/j.jnci.2016.08.003] [PMID: 27634416]
[46]
Duffy, M.J.; O’Byrne, K. Tissue and blood biomarkers in lung cancer: a review. Adv. Clin. Chem., 2018, 86, 1-21.
[http://dx.doi.org/10.1016/bs.acc.2018.05.001] [PMID: 30144837]
[47]
Villalobos, P.; Wistuba, I.I. Lung cancer biomarkers. Hematol. Oncol. Clin. North Am., 2017, 31(1), 13-29.
[http://dx.doi.org/10.1016/j.hoc.2016.08.006] [PMID: 27912828]
[48]
Cameron, S.J.S.; Lewis, K.E.; Beckmann, M.; Allison, G.G.; Ghosal, R.; Lewis, P.D.; Mur, L.A.J. The metabolomic detection of lung cancer biomarkers in sputum. Lung Cancer, 2016, 94, 88-95.
[http://dx.doi.org/10.1016/j.lungcan.2016.02.006] [PMID: 26973212]
[49]
Chen, Y.; Ma, Z.; Min, L.; Li, H.; Wang, B.; Zhong, J.; Dai, L. Biomarker identification and pathway analysis by serum metabolomics of lung cancer. BioMed Res. Int., 2015, 2015, 183624
[http://dx.doi.org/10.1155/2015/183624] [PMID: 25961003]
[50]
Zare, M.; Mostafaei, S.; Ahmadi, A.; Azimzadeh Jamalkandi, S.; Abedini, A.; Esfahani-Monfared, Z.; Dorostkar, R.; Saadati, M. Human endogenous retrovirus env genes: Potential blood biomarkers in lung cancer. Microb. Pathog., 2018, 115, 189-193.
[http://dx.doi.org/10.1016/j.micpath.2017.12.040] [PMID: 29274460]
[51]
Jiang, N.; Meng, X.; Mi, H.; Chi, Y.; Li, S.; Jin, Z.; Tian, H.; He, J.; Shen, W.; Tian, H.; Pan, J.; Fang, S.; Jin, X.; Zhou, C.; Gong, Z. Circulating lncRNA XLOC_009167 serves as a diagnostic biomarker to predict lung cancer. Clin. Chim. Acta, 2018, 486, 26-33.
[http://dx.doi.org/10.1016/j.cca.2018.07.026] [PMID: 30025752]
[52]
Zhang, J.; Han, X.; Gao, C.; Xing, Y.; Qi, Z.; Liu, R.; Wang, Y.; Zhang, X.; Yang, Y.G.; Li, X.; Sun, B.; Tian, X. 5-Hydroxymethylome in circulating cell-free DNA as a potential biomarker for non-small-cell lung cancer. Genomics Proteomics Bioinformatics, 2018, 16(3), 187-199.
[http://dx.doi.org/10.1016/j.gpb.2018.06.002] [PMID: 30010036]
[53]
Soliman, S.E.; Alhanafy, A.M.; Habib, M.S.E.; Hagag, M.; Ibrahem, R.A.L.; Ibrahem, R.A.L. Serum circulating cell free DNA as potential diagnostic and prognostic biomarker in non small cell lung cancer. Biochem. Biophys. Rep., 2018, 15, 45-51.
[http://dx.doi.org/10.1016/j.bbrep.2018.06.002] [PMID: 29984326]
[54]
Association, A. 2018 Alzheimer’s disease facts and figures. Alzheimers Dement., 2018, 14(3), 367-429.
[http://dx.doi.org/10.1016/j.jalz.2018.02.001]
[55]
Tramutola, A.; Triani, F.; Di Domenico, F.; Barone, E.; Cai, J.; Klein, J.B.; Perluigi, M.; Butterfield, D.A. Poly-ubiquitin profile in Alzheimer disease brain. Neurobiol. Dis., 2018, 118(3), 129-141.
[http://dx.doi.org/10.1016/j.nbd.2018.07.006] [PMID: 30003951]
[56]
Grøntvedt, G.R.; Schröder, T.N.; Sando, S.B.; White, L.; Bråthen, G.; Doeller, C.F. Alzheimer’s disease. Curr. Biol., 2018, 28(11), R645-R649.
[http://dx.doi.org/10.1016/j.cub.2018.04.080] [PMID: 29870699]
[57]
Sangubotla, R.; Kim, J. Recent trends in analytical approaches for detecting neurotransmitters in Alzheimer’s disease. Trends Analyt. Chem., 2018, 105, 240-250.
[http://dx.doi.org/10.1016/j.trac.2018.05.014]
[58]
Hanon, O.; Vidal, J.S.; Lehmann, S.; Bombois, S.; Allinquant, B.; Tréluyer, J.M.; Gelé, P.; Delmaire, C.; Blanc, F.; Mangin, J.F.; Buée, L.; Touchon, J.; Hugon, J.; Vellas, B.; Galbrun, E.; Benetos, A.; Berrut, G.; Paillaud, E.; Wallon, D.; Castelnovo, G.; Volpe-Gillot, L.; Paccalin, M.; Robert, P.H.; Godefroy, O.; Dantoine, T.; Camus, V.; Belmin, J.; Vandel, P.; Novella, J.L.; Duron, E.; Rigaud, A.S.; Schraen-Maschke, S.; Gabelle, A. BALTAZAR study group. Plasma amyloid levels within the Alzheimer’s process and correlations with central biomarkers. Alzheimers Dement., 2018, 14(7), 858-868.
[http://dx.doi.org/10.1016/j.jalz.2018.01.004] [PMID: 29458036]
[59]
Pekeles, H.; Qureshi, H.Y.; Paudel, H.K.; Schipper, H.M.; Gornistky, M.; Chertkow, H. Development and validation of a salivary tau biomarker in Alzheimer’s disease. Alzheimers Dement. (Amst.), 2018, 11, 53-60.
[http://dx.doi.org/10.1016/j.dadm.2018.03.003] [PMID: 30623019]
[60]
Luca, M.; Luca, A.; Calandra, C. The role of oxidative damage in the pathogenesis and progression of Alzheimer’s disease and vascular dementia. Oxid. Med. Cell. Longev., 2015, 2015, 504678
[http://dx.doi.org/10.1155/2015/504678] [PMID: 26301043]
[61]
Peña-Bautista, C.; Vigor, C.; Galano, J.M.; Oger, C.; Durand, T.; Ferrer, I.; Cuevas, A.; López-Cuevas, R.; Baquero, M.; López-Nogueroles, M.; Vento, M.; Hervás, D.; García-Blanco, A.; Cháfer-Pericás, C. Plasma lipid peroxidation biomarkers for early and non-invasive Alzheimer Disease detection. Free Radic. Biol. Med., 2018, 124, 388-394.
[http://dx.doi.org/10.1016/j.freeradbiomed.2018.06.038] [PMID: 29969716]
[62]
García-Blanco, A.; Peña-Bautista, C.; Oger, C.; Vigor, C.; Galano, J.M.; Durand, T.; Martín-Ibáñez, N.; Baquero, M.; Vento, M.; Cháfer-Pericás, C. Reliable determination of new lipid peroxidation compounds as potential early Alzheimer Disease biomarkers. Talanta, 2018, 184, 193-201.
[http://dx.doi.org/10.1016/j.talanta.2018.03.002] [PMID: 29674032]
[63]
Deng, H.; Wang, P.; Jankovic, J. The genetics of Parkinson disease. Ageing Res. Rev., 2018, 42, 72-85.
[http://dx.doi.org/10.1016/j.arr.2017.12.007] [PMID: 29288112]
[64]
Schulz-Schaeffer, W.J. Is cell death primary or secondary in the pathophysiology of idiopathic Parkinson’s disease? Biomolecules, 2015, 5(3), 1467-1479.
[http://dx.doi.org/10.3390/biom5031467] [PMID: 26193328]
[65]
Scorza, F.A.; Fiorini, A.C.; Scorza, C.A.; Finsterer, J. Cardiac abnormalities in Parkinson’s disease and Parkinsonism. J. Clin. Neurosci., 2018, 53, 1-5.
[http://dx.doi.org/10.1016/j.jocn.2018.04.031] [PMID: 29706419]
[66]
Kalia, L.V. Biomarkers for cognitive dysfunction in Parkinson’s disease. Parkinsonism Relat. Disord., 2018, 46(Suppl. 1), S19-S23.
[http://dx.doi.org/10.1016/j.parkreldis.2017.07.023] [PMID: 28781202]
[67]
Wang, X.; Yu, S.; Li, F.; Feng, T. Detection of α-synuclein oligomers in red blood cells as a potential biomarker of Parkinson’s disease. Neurosci. Lett., 2015, 599, 115-119.
[http://dx.doi.org/10.1016/j.neulet.2015.05.030] [PMID: 25998655]
[68]
Papagiannakis, N.; Koros, C.; Stamelou, M.; Simitsi, A.M.; Maniati, M.; Antonelou, R.; Papadimitriou, D.; Dermentzaki, G.; Moraitou, M.; Michelakakis, H.; Stefanis, L. Alpha-synuclein dimerization in erythrocytes of patients with genetic and non-genetic forms of Parkinson’s Disease. Neurosci. Lett., 2018, 672, 145-149.
[http://dx.doi.org/10.1016/j.neulet.2017.11.012] [PMID: 29129675]
[69]
Zhao, H.; Wang, C.; Zhao, N.; Li, W.; Yang, Z.; Liu, X.; Le, W.; Zhang, X. Potential biomarkers of Parkinson’s disease revealed by plasma metabolic profiling. J. Chromatogr. B Analyt. Technol. Biomed. Life Sci., 2018, 1081-1082, 101-108.
[http://dx.doi.org/10.1016/j.jchromb.2018.01.025] [PMID: 29518718]
[70]
Campolo, J.; De Maria, R.; Cozzi, L.; Parolini, M.; Bernardi, S.; Proserpio, P.; Nobili, L.; Gelosa, G.; Piccolo, I.; Agostoni, E.C.; Trivella, M.G.; Marraccini, P. Antioxidant and inflammatory biomarkers for the identification of prodromal Parkinson’s disease. J. Neurol. Sci., 2016, 370, 167-172.
[http://dx.doi.org/10.1016/j.jns.2016.09.050] [PMID: 27772753]
[71]
Ho, D.H.; Yi, S.; Seo, H.; Son, I.; Seol, W. Increased DJ-1 in urine exosome of Korean males with Parkinson’s disease. BioMed Res. Int., 2014, 2014, 704678
[http://dx.doi.org/10.1155/2014/704678] [PMID: 25478574]
[72]
Fraser, K.B.; Rawlins, A.B.; Clark, R.G.; Alcalay, R.N.; Standaert, D.G.; Liu, N.; West, A.B.; West, A.B. Parkinson’s Disease Biomarker Program Consortium. Ser(P)-1292 LRRK2 in urinary exosomes is elevated in idiopathic Parkinson’s disease. Mov. Disord., 2016, 31(10), 1543-1550.
[http://dx.doi.org/10.1002/mds.26686] [PMID: 27297049]
[73]
Lavie, C.J.; De Schutter, A.; Parto, P.; Jahangir, E.; Kokkinos, P.; Ortega, F.B.; Arena, R.; Milani, R.V. Obesity and prevalence of cardiovascular diseases and prognosis - the obesity paradox updated. Prog. Cardiovasc. Dis., 2016, 58(5), 537-547.
[http://dx.doi.org/10.1016/j.pcad.2016.01.008] [PMID: 26826295]
[74]
Fathil, M.F.M.; Md Arshad, M.K.; Gopinath, S.C.B.; Hashim, U.; Adzhri, R.; Ayub, R.M.; Ruslinda, A.R.; Nuzaihan M N, M.; Azman, A.H.; Zaki, M.; Tang, T.H. Diagnostics on acute myocardial infarction: Cardiac troponin biomarkers. Biosens. Bioelectron., 2015, 70, 209-220.
[http://dx.doi.org/10.1016/j.bios.2015.03.037] [PMID: 25841117]
[75]
Yang, Z.; Wang, H.; Guo, P.; Ding, Y.; Lei, C.; Luo, Y. A Multi-region magnetoimpedance-based bio-analytical system for ultrasensitive simultaneous determination of cardiac biomarkers myoglobin and C-reactive protein. Sensors (Basel), 2018, 18(6), 1765-1777.
[http://dx.doi.org/10.3390/s18061765] [PMID: 29857573]
[76]
Akinkuolie, A.O.; Buring, J.E.; Ridker, P.M.; Mora, S. A novel protein glycan biomarker and future cardiovascular disease events. J. Am. Heart Assoc., 2014, 3(5), e001221
[http://dx.doi.org/10.1161/JAHA.114.001221] [PMID: 25249300]
[77]
Trpkovic, A.; Resanovic, I.; Stanimirovic, J.; Radak, D.; Mousa, S.A.; Cenic-Milosevic, D.; Jevremovic, D.; Isenovic, E.R. Oxidized low-density lipoprotein as a biomarker of cardiovascular diseases. Crit. Rev. Clin. Lab. Sci., 2015, 52(2), 70-85.
[http://dx.doi.org/10.3109/10408363.2014.992063] [PMID: 25537066]
[78]
Romaine, S.P.R.; Tomaszewski, M.; Condorelli, G.; Samani, N.J. MicroRNAs in cardiovascular disease: an introduction for clinicians. Heart, 2015, 101(12), 921-928.
[http://dx.doi.org/10.1136/heartjnl-2013-305402] [PMID: 25814653]
[79]
Di Angelantonio, E.; Gao, P.; Khan, H.; Butterworth, A.S.; Wormser, D.; Kaptoge, S.; Kondapally Seshasai, S.R.; Thompson, A.; Sarwar, N.; Willeit, P.; Ridker, P.M.; Barr, E.L.; Khaw, K.T.; Psaty, B.M.; Brenner, H.; Balkau, B.; Dekker, J.M.; Lawlor, D.A.; Daimon, M.; Willeit, J.; Njølstad, I.; Nissinen, A.; Brunner, E.J.; Kuller, L.H.; Price, J.F.; Sundström, J.; Knuiman, M.W.; Feskens, E.J.; Verschuren, W.M.; Wald, N.; Bakker, S.J.; Whincup, P.H.; Ford, I.; Goldbourt, U.; Gómez-de-la-Cámara, A.; Gallacher, J.; Simons, L.A.; Rosengren, A.; Sutherland, S.E.; Björkelund, C.; Blazer, D.G.; Wassertheil-Smoller, S.; Onat, A.; Marín Ibañez, A.; Casiglia, E.; Jukema, J.W.; Simpson, L.M.; Giampaoli, S.; Nordestgaard, B.G.; Selmer, R.; Wennberg, P.; Kauhanen, J.; Salonen, J.T.; Dankner, R.; Barrett-Connor, E.; Kavousi, M.; Gudnason, V.; Evans, D.; Wallace, R.B.; Cushman, M.; D’Agostino, R.B., Sr; Umans, J.G.; Kiyohara, Y.; Nakagawa, H.; Sato, S.; Gillum, R.F.; Folsom, A.R.; van der Schouw, Y.T.; Moons, K.G.; Griffin, S.J.; Sattar, N.; Wareham, N.J.; Selvin, E.; Thompson, S.G.; Danesh, J. Emerging Risk Factors Collaboration. Glycated hemoglobin measurement and prediction of cardiovascular disease. JAMA, 2014, 311(12), 1225-1233.
[http://dx.doi.org/10.1001/jama.2014.1873] [PMID: 24668104]
[80]
Furuhashi, M.; Saitoh, S.; Shimamoto, K.; Miura, T. Fatty acid-binding protein 4 (FABP4): pathophysiological insights and potent clinical biomarker of metabolic and cardiovascular diseases. Clin. Med. Insights Cardiol., 2015, 8(Suppl. 3), 23-33.
[PMID: 25674026]
[81]
Adela, R.; Banerjee, S.K. GDF-15 as a target and biomarker for diabetes and cardio-vascular diseases: a translational prospective. J. Diabetes Res., 2015, 2015, 490842
[http://dx.doi.org/10.1155/2015/490842] [PMID: 26273671]
[82]
Wollert, K.C.; Kempf, T.; Wallentin, L. Growth differentiation factor 15 as a biomarker in cardiovascular disease. Clin. Chem., 2017, 63(1), 140-151.
[http://dx.doi.org/10.1373/clinchem.2016.255174] [PMID: 28062617]
[83]
Schulte, C.; Zeller, T. microRNA-based diagnostics and therapy in cardiovascular disease-Summing up the facts. Cardiovasc. Diagn. Ther., 2015, 5(1), 17-36.
[PMID: 25774345]
[84]
Navickas, R.; Gal, D.; Laucevičius, A.; Taparauskaitė, A.; Zdanytė, M.; Holvoet, P. Identifying circulating microRNAs as biomarkers of cardiovascular disease: a systematic review. Cardiovasc. Res., 2016, 111(4), 322-337.
[http://dx.doi.org/10.1093/cvr/cvw174] [PMID: 27357636]
[85]
Olson, E.N. MicroRNAs as therapeutic targets and biomarkers of cardiovascular disease. Sci. Transl. Med., 2014, 6(239), 239ps3
[http://dx.doi.org/10.1126/scitranslmed.3009008] [PMID: 24898744]
[86]
Wang, G.K.; Zhu, J.Q.; Zhang, J.T.; Li, Q.; Li, Y.; He, J.; Qin, Y.W.; Jing, Q. Circulating microRNA: a novel potential biomarker for early diagnosis of acute myocardial infarction in humans. Eur. Heart J., 2010, 31(6), 659-666.
[http://dx.doi.org/10.1093/eurheartj/ehq013] [PMID: 20159880]
[87]
Zhang, L.; Chen, X.; Su, T.; Li, H.; Huang, Q.; Wu, D.; Yang, C.; Han, Z. Circulating miR-499 are novel and sensitive biomarker of acute myocardial infarction. J. Thorac. Dis., 2015, 7(3), 303-308.
[PMID: 25922707]
[88]
Baccarelli, A.A.; Byun, H.M. Platelet mitochondrial DNA methylation: a potential new marker of cardiovascular disease. Clin. Epigenetics, 2015, 7, 44-53.
[http://dx.doi.org/10.1186/s13148-015-0078-0] [PMID: 25901189]
[89]
Altintas, Z.; Tothill, I.E. Molecular biosensors: promising new tools for early detection of cancer. NDD, 2015, 4, 1-10.
[http://dx.doi.org/10.2147/NDD.S56772]
[90]
Sang, S.; Wang, Y.; Feng, Q.; Wei, Y.; Ji, J.; Zhang, W. Progress of new label-free techniques for biosensors: a review. Crit. Rev. Biotechnol., 2016, 36(3), 465-481.
[PMID: 25608959]
[91]
Bhakta, S.A.; Evans, E.; Benavidez, T.E.; Garcia, C.D. Protein adsorption onto nanomaterials for the development of biosensors and analytical devices: a review. Anal. Chim. Acta, 2015, 872, 7-25.
[http://dx.doi.org/10.1016/j.aca.2014.10.031] [PMID: 25892065]
[92]
Patel, S.; Nanda, R.; Sahoo, S.; Mohapatra, E. Biosensors in health care: the milestones achieved in their development towards lab-on-chip-analysis. Biochem. Res. Int., 2016, 2016, 3130469
[http://dx.doi.org/10.1155/2016/3130469] [PMID: 27042353]
[93]
Holzinger, M.; Le Goff, A.; Cosnier, S. Nanomaterials for biosensing applications: a review. Front Chem., 2014, 2, 63.
[http://dx.doi.org/10.3389/fchem.2014.00063] [PMID: 25221775]
[94]
Liu, Y.; Yu, J. Oriented immobilization of proteins on solid supports for use in biosensors and biochips: a review. Mikrochim. Acta, 2016, 183, 1-19.
[http://dx.doi.org/10.1007/s00604-015-1623-4]
[95]
Sallam, R.M. Proteomics in cancer biomarkers discovery: challenges and applications. Dis. Markers, 2015, 2015, 321370
[http://dx.doi.org/10.1155/2015/321370] [PMID: 25999657]
[96]
Liang, Y.H.; Chang, C.C.; Chen, C.C.; Chu-Su, Y.; Lin, C.W. Development of an Au/ZnO thin film surface plasmon resonance-based biosensor immunoassay for the detection of carbohydrate antigen 15-3 in human saliva. Clin. Biochem., 2012, 45(18), 1689-1693.
[http://dx.doi.org/10.1016/j.clinbiochem.2012.09.001] [PMID: 22981930]
[97]
Cardoso, A.R.; Moreira, F.T.C.; Fernandes, R.; Sales, M.G.F. Novel and simple electrochemical biosensor monitoring attomolar levels of miRNA-155 in breast cancer. Biosens. Bioelectron., 2016, 80, 621-630.
[http://dx.doi.org/10.1016/j.bios.2016.02.035] [PMID: 26901459]
[98]
Jia, X.; Chen, J.; Sun, S.; Yang, W.; Yang, S.; Shah, P.; Hoti, N.; Veltri, B.; Zhang, H. Detection of aggressive prostate cancer associated glycoproteins in urine using glycoproteomics and mass spectrometry. Proteomics, 2016, 16(23), 2989-2996.
[http://dx.doi.org/10.1002/pmic.201500506] [PMID: 27749016]
[99]
Kailemia, M.J.; Park, D.; Lebrilla, C.B. Glycans and glycoproteins as specific biomarkers for cancer. Anal. Bioanal. Chem., 2017, 409(2), 395-410.
[http://dx.doi.org/10.1007/s00216-016-9880-6] [PMID: 27590322]
[100]
Silva, P.M.S.; Lima, A.L.R.; Silva, B.V.M.; Coelho, L.C.B.B.; Dutra, R.F.; Correia, M.T.S. Cratylia mollis lectin nanoelectrode for differential diagnostic of prostate cancer and benign prostatic hyperplasia based on label-free detection. Biosens. Bioelectron., 2016, 85, 171-177.
[http://dx.doi.org/10.1016/j.bios.2016.05.004] [PMID: 27176915]
[101]
Joshi, G.K.; Deitz-McElyea, S.; Johnson, M.; Mali, S.; Korc, M.; Sardar, R. Highly specific plasmonic biosensors for ultrasensitive microRNA detection in plasma from pancreatic cancer patients. Nano Lett., 2014, 14(12), 6955-6963.
[http://dx.doi.org/10.1021/nl503220s] [PMID: 25379951]
[102]
Ortega, F.G.; Fernández-Baldo, M.A.; Serrano, M.J.; Lorente, J.A.; Raba, J. Epithelial cancer biomarker EpCAM determination in peripheral blood samples using a microfluidic immunosensor based in silver nanoparticles as platform. Sens. Actuators B Chem., 2015, 221, 248-256.
[http://dx.doi.org/10.1016/j.snb.2015.06.066]
[103]
Li, S.S.; Lin, C.W.; Wei, K.C.; Huang, C.Y.; Hsu, P.H.; Liu, H.L.; Lu, Y.J.; Lin, S.C.; Yang, H.W.; Ma, C.C. Non-invasive screening for early Alzheimer’s disease diagnosis by a sensitively immunomagnetic biosensor. Sci. Rep., 2016, 6, 25155.
[http://dx.doi.org/10.1038/srep25155] [PMID: 27112198]
[104]
Sun, L.; Zhong, Y.; Gui, J.; Wang, X.; Zhuang, X.; Weng, J. A hydrogel biosensor for high selective and sensitive detection of amyloid-beta oligomers. Int. J. Nanomedicine, 2018, 13, 843-856.
[http://dx.doi.org/10.2147/IJN.S152163] [PMID: 29467574]
[105]
Kumar, V.; Brent, J.R.; Shorie, M.; Kaur, H.; Chadha, G.; Thomas, A.G.; Lewis, E.A.; Rooney, A.P.; Nguyen, L.; Zhong, X.L.; Burke, M.G.; Haigh, S.J.; Walton, A.; McNaughter, P.D.; Tedstone, A.A.; Savjani, N.; Muryn, C.A.; O’Brien, P.; Ganguli, A.K.; Lewis, D.J.; Sabherwal, P. Nanostructured aptamer-functionalized black phosphorus sensing platform for label- free detection of myoglobin, a cardiovascular disease biomarker. ACS Appl. Mater. Interfaces, 2016, 8(35), 22860-22868.
[http://dx.doi.org/10.1021/acsami.6b06488] [PMID: 27508925]
[106]
Jo, H.; Her, J.; Lee, H.; Shim, Y.B.; Ban, C. Highly sensitive amperometric detection of cardiac troponin I using sandwich aptamers and screen-printed carbon electrodes. Talanta, 2017, 165, 442-448.
[http://dx.doi.org/10.1016/j.talanta.2016.12.091] [PMID: 28153281]
[107]
Marusov, G.; Sweatt, A.; Pietrosimone, K.; Benson, D.; Geary, S.J.; Silbart, L.K.; Challa, S.; Lagoy, J.; Lawrence, D.A.; Lynes, M.A. A microarray biosensor for multiplexed detection of microbes using grating-coupled surface plasmon resonance imaging. Environ. Sci. Technol., 2012, 46(1), 348-359.
[http://dx.doi.org/10.1021/es201239f] [PMID: 22029256]
[108]
Huertas, C.S.; Domínguez-Zotes, S.; Lechuga, L.M. Analysis of alternative splicing events for cancer diagnosis using a multiplexing nanophotonic biosensor. Sci. Rep., 2017, 7, 41368-41376.
[http://dx.doi.org/10.1038/srep41368] [PMID: 28120920]
[109]
Marcotte, T.D.; Deutsch, R.; Michael, B.D.; Franklin, D.; Cookson, D.R.; Bharti, A.R.; Grant, I.; Letendre, S.L. CHARTER Group. A concise panel of biomarkers identifies neurocognitive functioning changes in HIV-infected individuals. J. Neuroimmune Pharmacol., 2013, 8(5), 1123-1135.
[http://dx.doi.org/10.1007/s11481-013-9504-2] [PMID: 24101401]
[110]
Jickling, G.C.; Sharp, F.R. Biomarker panels in ischemic stroke. Stroke, 2015, 46(3), 915-920.
[http://dx.doi.org/10.1161/STROKEAHA.114.005604] [PMID: 25657186]
[111]
Liang, L.; Su, M.; Li, L.; Lan, F.; Yang, G.; Ge, S.; Yu, J.; Song, X. Aptamer-based fluorescent and visual biosensor for multiplexed monitoring of cancer cells in microfluidic paper-based analytical devices. Sens. Actuators B Chem., 2016, 229, 347-354.
[http://dx.doi.org/10.1016/j.snb.2016.01.137]
[112]
Doong, R.A.; Lee, P.S.; Anitha, K. Simultaneous determination of biomarkers for Alzheimer’s disease using sol-gel-derived optical array biosensor. Biosens. Bioelectron., 2010, 25(11), 2464-2469.
[http://dx.doi.org/10.1016/j.bios.2010.04.005] [PMID: 20444591]
[113]
Yesilkoy, F.; Terborg, R.A.; Pello, J.; Belushkin, A.A.; Jahani, Y.; Pruneri, V.; Altug, H. Phase-sensitive plasmonic biosensor using a portable and large field-of-view interferometric microarray imager. Light Sci. Appl., 2018, 7, 17152-17161.
[http://dx.doi.org/10.1038/lsa.2017.152] [PMID: 30839537]


Rights & PermissionsPrintExport Cite as

Article Details

VOLUME: 27
ISSUE: 21
Year: 2020
Published on: 15 June, 2020
Page: [3519 - 3533]
Pages: 15
DOI: 10.2174/0929867326666190124103125
Price: $65

Article Metrics

PDF: 23
HTML: 2